Alcidion Group (ASX:ALC) PB Ratio: 1.43 (As of Jun. 26, 2026) — 71% Below Median


What is Alcidion Group PB Ratio?

Alcidion Group ASX:ALC +1.05% PB Ratio is 1.43 as of Jun. 26, 2026, which is 71% below its 10-year median of 4.99. The stock has 4 warning signs investors should review. Among 611 Healthcare Providers & Services companies, Alcidion Group ranks better than 63.99% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Alcidion Group's share price is A$0.096. Alcidion Group's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.07. Hence, Alcidion Group's PB Ratio of today is 1.43.

Good Sign:

Alcidion Group Ltd stock PB Ratio (=1.46) is close to 1-year low of 1.37.

The historical rank and industry rank for Alcidion Group's PB Ratio or its related term are showing as below:

ASX:ALC' s PB Ratio Range Over the Past 10 Years
Min: 0.63   Med: 4.99   Max: 26.49
Current: 1.43

During the past 13 years, Alcidion Group's highest PB Ratio was 26.49. The lowest was 0.63. And the median was 4.99.

ASX:ALC's PB Ratio is ranked better than
63.99% of 611 companies
in the Healthcare Providers & Services industry
Industry Median: 1.98 vs ASX:ALC: 1.43

During the past 12 months, Alcidion Group's average Book Value Per Share Growth Rate was 4.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -4.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 16.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 24.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Alcidion Group was 103.30% per year. The lowest was -43.00% per year. And the median was 13.30% per year.

Back to Basics: PB Ratio


Alcidion Group  (ASX:ALC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Alcidion Group PB Ratio Related Terms


Alcidion Group PB Ratio Historical Data

* Premium members only.

The historical data trend for Alcidion Group's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alcidion Group PB Ratio Chart

Alcidion Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.34 1.49 1.34 0.74 1.54

Alcidion Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.74 0.94 1.54 1.57

ASX:ALC vs VEEV, BTSG, TEM: PB Ratio Comparison

For the Health Information Services subindustry, Alcidion Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alcidion Group PB Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Alcidion Group's PB Ratio distribution charts can be found below:

* The bar in red indicates where Alcidion Group's PB Ratio falls into.



Alcidion Group PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Alcidion Group's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.096/0.067
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 1.43 mean?
Alcidion Group (ASX:ALC) has a PB Ratio of 1.43 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alcidion Group and its competitors. This is 71% below median its historical median of 4.99. Over the past decade, Alcidion Group's PB Ratio has ranged from 0.63 to 26.49. According to the industry distribution chart, Alcidion Group ranks #220 out of 611 companies in the Healthcare Providers & Services industry, placing it in the top 36%.
Is Alcidion Group's PB Ratio too high?
Alcidion Group's current PB Ratio of 1.43 is 71% below median its 10-year median of 4.99. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 26.49. The Healthcare Providers & Services industry median PB Ratio is 1.98. Alcidion Group's value of 1.43 is 27.8% below this industry median. Based on the distribution chart, Alcidion Group ranks #220 out of 611 companies in the Healthcare Providers & Services industry, which is above the industry midpoint.
How does Alcidion Group's PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Alcidion Group ranks #220 out of 611 companies for PB Ratio. This puts Alcidion Group in the upper half of its industry. The industry median PB Ratio is 1.98. Alcidion Group's value of 1.43 is 27.8% below this benchmark. Historically, Alcidion Group's own PB Ratio has ranged from 0.63 to 26.49 over the past decade. While the company's 10-year median is 4.99 vs. the industry median of 1.98, Alcidion Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.98, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcidion Group's current PB Ratio of 1.43 is 27.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alcidion Group and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcidion Group's current PB Ratio is 1.43, which is 71% below median its own 10-year median of 4.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcidion Group stock overvalued right now?
Based on GuruFocus' analysis, Alcidion Group (ASX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.12, compared to a current price of A$0.10 — trading 20% below its estimated fair value. The current PB Ratio is 1.43, which is 71% below median its 10-year median of 4.99 and 27.8% below the Healthcare Providers & Services industry median of 1.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alcidion Group (ASX:ALC), the current PB Ratio is 1.43 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alcidion Group Business Description

Address 9 Yarra Street, Level 10, South Yarra, Melbourne, VIC, AUS, 3141
Alcidion Group Ltd is a provider of intelligent informatics software. It offers a fully integrated digital patient care platform that includes a clinical decision support (CDS) system, Electronic Patient Record (EPR), and Patient Administration System (PAS). Alcidion is engaged in the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of healthcare software products from its strategic partners, and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in the United Kingdom, Australia, and New Zealand. The company generates maximum revenue from the United Kingdom.